{"id":"saffron-tablet","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal upset"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Dry mouth"}]},"_chembl":{"chemblId":"CHEMBL635","moleculeType":"Small molecule","molecularWeight":"358.43"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The active compounds in saffron, particularly crocin and safranal, work by scavenging free radicals and reducing oxidative stress, while also modulating inflammatory pathways and potentially affecting monoamine neurotransmitter systems. These mechanisms contribute to its reported benefits in mood disorders, cognitive function, and various inflammatory conditions. The exact molecular targets remain incompletely characterized, but evidence suggests involvement of multiple pathways rather than a single receptor or enzyme.","oneSentence":"Saffron (Crocus sativus) exerts therapeutic effects primarily through its active constituents crocin and safranal, which possess antioxidant, anti-inflammatory, and neuroprotective properties.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:06:30.304Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Depression (mild to moderate)"},{"name":"Cognitive dysfunction"},{"name":"Age-related macular degeneration"}]},"trialDetails":[{"nctId":"NCT05199545","phase":"NA","title":"Efficacy Study in Phytotherapy of an Association of Plants in the Improvement of Psychological Well-being","status":"COMPLETED","sponsor":"Larena SAS","startDate":"2022-04-26","conditions":"Psychological Well-being","enrollment":126},{"nctId":"NCT06240364","phase":"NA","title":"Effects of AffronEye®/ Crocuvis+® on Dry Eye Syndrome","status":"NOT_YET_RECRUITING","sponsor":"University of Alicante","startDate":"2025-10-10","conditions":"Dry Eye Syndrome","enrollment":204},{"nctId":"NCT05261399","phase":"PHASE3","title":"Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2022-08-03","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":324},{"nctId":"NCT06187818","phase":"","title":"Follow up Study of Crocin on Cardiac Function Protection in Patients With Breast Cancer Undergoing Neoadjuvant Chemotherapy Based on Color Doppler Ultrasound Combined With Myocardial Zymogram","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mei Zhang","startDate":"2023-09-01","conditions":"Breast Cancer","enrollment":120},{"nctId":"NCT05211063","phase":"NA","title":"Effects of CROCUVIS+® on Computer Vision Syndrome, Sleep and Mood Disorders","status":"COMPLETED","sponsor":"University of Alicante","startDate":"2022-10-21","conditions":"Computer Vision Syndrome, Sleep Disorder, Mood Disorders","enrollment":100},{"nctId":"NCT05504148","phase":"NA","title":"Protection of Cardiovascular Function With Crocin in BrEast Cancer Patients Undergoing Radiotherapy and Chemotherapy","status":"UNKNOWN","sponsor":"Qilu Hospital of Shandong University","startDate":"2021-03-29","conditions":"Breast Cancer","enrollment":120},{"nctId":"NCT05117749","phase":"PHASE2","title":"Saffron and Ulcerative Colitis","status":"UNKNOWN","sponsor":"Shiraz University of Medical Sciences","startDate":"2023-05","conditions":"Ulcerative Colitis","enrollment":60},{"nctId":"NCT03372109","phase":"NA","title":"Evaluate the Effects of Repeated Periods of Modified Fasting to Support Healthy Natural Weight Management and Prevention of Weight Gain","status":"COMPLETED","sponsor":"Supplement Formulators, Inc.","startDate":"2017-11-14","conditions":"Body Weight Changes","enrollment":23},{"nctId":"NCT01625442","phase":"PHASE4","title":"Crocus Sativus (Saffron) and Berberis Vulgaris (Barberry Fruit) in Metabolic Syndrome","status":"COMPLETED","sponsor":"Birjand University of Medical Sciences","startDate":"2010-01","conditions":"Metabolic Syndrome, Hypercholesterolemia, Hypertriglyceridemia","enrollment":732}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":17,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["crocin","safranal"],"phase":"marketed","status":"active","brandName":"Saffron tablet","genericName":"Saffron tablet","companyName":"Birjand University of Medical Sciences","companyId":"birjand-university-of-medical-sciences","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Saffron (Crocus sativus) exerts therapeutic effects primarily through its active constituents crocin and safranal, which possess antioxidant, anti-inflammatory, and neuroprotective properties. Used for Depression (mild to moderate), Cognitive dysfunction, Age-related macular degeneration.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}